NMIBC: A Comprehensive Look at the Treatment, Therapeutic Landscape
NMIBC: A Comprehensive Look at the Treatment, Therapeutic Landscape

At the AUA 2025 Annual Meeting, Patrick Gomella, MD, Thomas Jefferson University Hospitals, and David Ambinder, MD, Medical College/Westchester Medical Center, provide a comprehensive overview of the growing and changing treatment landscape for non-muscle invasive bladder cancer.

They begin with a review of the growth in this field over the past 10 years and continue through options available after BCG failure as well as bladder-sparing options for these patients, among other topics.

Advertisement

Latest News

Redefining Prostate Cancer Staging: PSMA PET in Real-World Practice
Redefining Prostate Cancer Staging: PSMA PET in Real-World Practice
Murilo De Almeida Luz, MDProstate Cancer | May 6, 2025
The panel discusses the role of PSMA PET imaging in staging and managing mHSPC, highlighting insurance barriers and more.
Guidelines for Measuring Patient Outcomes and Quality Improvements in GU Oncology
Guidelines for Measuring Patient Outcomes and Quality Improvements in GU Oncology
Mohummad Siddiqui, MDUrothelial Carcinoma | May 5, 2025
Mohummad Siddiqui, MD, discusses his work with the Commission on Cancer and their development on standards of care.
ctDNA in GU Oncology: History, Current Studies, and Benefits
ctDNA in GU Oncology: History, Current Studies, and Benefits
John Sfakianos, MDUrothelial Carcinoma Diagnostics | May 5, 2025
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
cT1a and cT1b-cT2 RCC: Who is at Risk of Upstaging to pT3a?
cT1a and cT1b-cT2 RCC: Who is at Risk of Upstaging to pT3a?
Victor Sandoval, MD, MScLocalized Renal Cell Carcinoma | May 5, 2025
Dr. Sandoval chats with David Ambinder, MD, on the upstaging of cT1b and cT2 tumors to pT3a.
Maximizing Benefits and Minimizing Harm: Reviewing AUA Guidelines on Prostate Cancer Early Detection
Maximizing Benefits and Minimizing Harm: Reviewing AUA Guidelines on Prostate Cancer Early Detection
Simpa Salami, MD, MPHProstate Cancer Diagnostics | May 5, 2025
Dr. Salami explains how updated guideline approaches shared decision-making in higher-risk groups.
Exploring Survival Outcomes of nccRCC With Tumor Thrombus Extension
Exploring Survival Outcomes of nccRCC With Tumor Thrombus Extension
Joseph Cheaib, MDnccRCC | May 5, 2025
Dr. Cheaib discusses outcomes in patients with non-clear cell RCC with tumor thrombus involvement after surgical treatment.
Radical Prostatectomy Versus Dose-Escalated Radiation With ADT in Node-Positive Prostate Cancer
Radical Prostatectomy Versus Dose-Escalated Radiation With ADT in Node-Positive Prostate Cancer
Arjun Pon Avudaiappan, MDLocalized | May 5, 2025
Dr. Avudaiappan compares radical prostatectomy with dose-escalated radiation with ADT for the treatment of prostate cancer.
SunRISe-1 Cohort 4: TAR-200 for BCG-Unresponsive Papillary NMIBC is Well-Tolerated
SunRISe-1 Cohort 4: TAR-200 for BCG-Unresponsive Papillary NMIBC is Well-Tolerated
Felix Guerrero-Ramos, MDUrothelial Carcinoma | May 5, 2025
At the AUA 2025 Annual Meeting, Dr. Guerrero-Ramos highlights the first results from Cohort 4 of SunRISe-1.
ARANOTE: Updated Data on Ultra-Low PSA Response
ARANOTE: Updated Data on Ultra-Low PSA Response
Neal Shore, MD, FACSmCSPC | May 2, 2025
Dr. Shore highlights post hoc analyses of ultra-low PSA responses and their correlation with outcomes in the ARANOTE study.
CREST: Sasanlimab Plus BCG for High-Risk NMIBC
CREST: Sasanlimab Plus BCG for High-Risk NMIBC
Neal Shore, MD, FACSUrothelial Carcinoma | May 2, 2025
Results of the CREST study show that sasanlimab plus BCG improves EFS compared with BCG alone in high-risk NMIBC.
Contextualizing N-803 Within the Treatment Paradigm for BCG-Unresponsive Bladder CIS
Contextualizing N-803 Within the Treatment Paradigm for BCG-Unresponsive Bladder CIS
Sam Chang, MDUrothelial Carcinoma | May 2, 2025
Drs. Chang and Joyce consider the role that N-803 now plays within the treatment paradigm for BCG-unresponsive bladder CIS.
QUILT-3.032: Complete Responses to N-803 Plus BCG in Bladder CIS With, Without Papillary Disease
QUILT-3.032: Complete Responses to N-803 Plus BCG in Bladder CIS With, Without Papillary Disease
Sam Chang, MDUrothelial Carcinoma | May 2, 2025
Drs. Chang, Joyce take a look at QUILT-3.032, including complete responses to N-803 plus BCG in BCG-unresponsive bladder CIS.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Katy Beckermann, MD, PhD
Katy Beckermann, MD, PhDEditor | Medical Director of GU Clinical Research at Tennessee Oncology
Christopher Wallis, MD, PhD, FRCSC
Christopher Wallis, MD, PhD, FRCSCAssistant Professor of Urology | University of Toronto
Akhil Abraham Saji, MD
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MD
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024
The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
James “Jim” Brugarolas, MD, PhDRenal Cell Carcinoma | April 22, 2025
Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | March 17, 2025
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Akhil Abraham Saji, MDLocalized | January 14, 2025
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
David Ambinder, MDLocalized | January 6, 2025
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.
Merging Clinical Trials With the Clinic: Bladder Cancer Therapeutic Advances With Dr. Brad McGregor
Merging Clinical Trials With the Clinic: Bladder Cancer Therapeutic Advances With Dr. Brad McGregor
Brad McGregor, MDMuscle Invasive Urothelial Carcinoma | August 14, 2024
Dr. Brad McGregor shares exciting developments in the MIBC space and the challenges facing the field of GU oncology.
Beyond the Operating Room: Compassionate Care, Leadership, and Mentorship in Urology With Dr. Christopher Kane
Beyond the Operating Room: Compassionate Care, Leadership, and Mentorship in Urology With Dr. Christopher Kane
Christopher Kane, MDProstate Cancer | March 24, 2025
Dr. Kane shares insights into his career trajectory, highlighting moments that led him to specialize and lead in urology.

Conference Coverage

Live meeting highlights

Guidelines for Measuring Patient Outcomes and Quality Improvements in GU Oncology
Mohummad Siddiqui, MDUrothelial Carcinoma | May 5, 2025
Mohummad Siddiqui, MD, discusses his work with the Commission on Cancer and their development on standards of care.
View More
ctDNA in GU Oncology: History, Current Studies, and Benefits
John Sfakianos, MDUrothelial Carcinoma Diagnostics | May 5, 2025
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
View More
cT1a and cT1b-cT2 RCC: Who is at Risk of Upstaging to pT3a?
Victor Sandoval, MD, MScLocalized Renal Cell Carcinoma | May 5, 2025
Dr. Sandoval chats with David Ambinder, MD, on the upstaging of cT1b and cT2 tumors to pT3a.
View More
Maximizing Benefits and Minimizing Harm: Reviewing AUA Guidelines on Prostate Cancer Early Detection
Simpa Salami, MD, MPHProstate Cancer Diagnostics | May 5, 2025
Dr. Salami explains how updated guideline approaches shared decision-making in higher-risk groups.
View More

Video Insights

Clinical discussions with experts in the field

Network Websites

Blood Cancers Today provides hematologists and oncologists with news, education, and research relevant to their patients and practices. Featuring the latest clinical updates from all facets of the specialty, it offers thought-provoking insights and exclusive interviews from experts in the field.

MashupMD is an innovative medical news and social media aggregator. The platform is optimized to deliver rapid access to the latest headlines in health care and collections of key medical content based on what health care professionals around the world are reading and sharing.

Cancer Nursing Today delivers critical news, research, and commentary to support oncology nurses throughout their education and careers. Its goal is to advance oncology treatments and care practices and promote the nurse’s role in enhanced patient outcomes and quality of life.

DocWire News is a leading source of medical industry news for health care professionals, featuring breaking news, expert commentary, research analysis, and conference highlights. It covers a comprehensive range of clinical specialties, including cardiology, oncology, neurology, and more.

Urban Health Today is the leading independent news source that provides urban health care professionals with relevant research and policy developments that impact patients and their practices. Its coverage focuses on clinical, social, and environmental health disparities.

Powered by DocWire News

GI Oncology Now is the leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies, offering the latest study data and research breakthroughs related to colorectal, gastric, liver, pancreatic, and esophageal cancers.

Heme Today produces the latest news and research for hematologists and oncologists focused on blood disorders such as clotting, red and white blood cell, and iron disorders, including conference highlights, late-breaking research, interviews with leaders in the field, and more.

A medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and data analysis to inform providers on the latest research and most effective clinical practices in the lung cancers space.

Nephrology Times delivers the latest news in nephrological treatments and technologies, curating content from clinical trials, conference highlights, and perspectives from key opinion leaders, with the goal of better informing care decisions and improving patient outcomes.

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |